Article
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer - 1 Oct 2016
Kang Min H, Reynolds C Patrick, Kolb E Anders, Gorlick Richard, Carol Hernan, Lock Richard, Keir Stephen T, Maris John M, Wu Jianwrong, Lyalin Dmitry, Kurmasheva Raushan T, Houghton Peter J, Smith Malcolm A
Abstract excerpt
BACKGROUND: MK-8242 is an inhibitor of MDM2 that stabilizes the tumor suppressor TP53 and induces growth arrest or apoptosis downstream of TP53 induction. PROCEDURES: MK-8242 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro cell line panel at concentrations from 1.0 nM to 10.0 μM and against the PPTP in vivo xenograft panels using oral gavage on Days 1-5 and Day 15-19 at a dose of 125...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.